Company Overview: LPath

Industry News

19 Apr

Lpath Reports Favorable Results from Phase 1 Study of Lpathomab

SAN DIEGO, April 19, 2016 /PRNewswire/ — Lpath, Inc. (LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of its Phase 1 double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab™ in healthy volunteers. Lpathomab was well tolerated at all doses...

Read more

1 Feb

Lpath Completes Dosing in the Lpathomab Phase 1 Safety Study

Lpathomab is well-tolerated at all doses tested in healthy volunteers SAN DIEGO, Feb. 1, 2016 /PRNewswire/ — Lpath, Inc. (LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of dosing in its Phase 1a double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address